178 related articles for article (PubMed ID: 23689710)
1. HIV-1 resistance mechanism to an electrostatically constrained peptide fusion inhibitor that is active against T-20-resistant strains.
Shimane K; Kawaji K; Miyamoto F; Oishi S; Watanabe K; Sakagami Y; Fujii N; Shimura K; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
Antimicrob Agents Chemother; 2013 Aug; 57(8):4035-8. PubMed ID: 23689710
[TBL] [Abstract][Full Text] [Related]
2. Electrostatically constrained alpha-helical peptide inhibits replication of HIV-1 resistant to enfuvirtide.
Nishikawa H; Nakamura S; Kodama E; Ito S; Kajiwara K; Izumi K; Sakagami Y; Oishi S; Ohkubo T; Kobayashi Y; Otaka A; Fujii N; Matsuoka M
Int J Biochem Cell Biol; 2009 Apr; 41(4):891-9. PubMed ID: 18834950
[TBL] [Abstract][Full Text] [Related]
3. SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide.
Naito T; Izumi K; Kodama E; Sakagami Y; Kajiwara K; Nishikawa H; Watanabe K; Sarafianos SG; Oishi S; Fujii N; Matsuoka M
Antimicrob Agents Chemother; 2009 Mar; 53(3):1013-8. PubMed ID: 19114674
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel fusion inhibitor against T-20-resistant HIV-1.
Oishi S; Ito S; Nishikawa H; Tanaka M; Ohno H; Otaka A; Izumi K; Kodama E; Matsuoka M; Fujii N
Adv Exp Med Biol; 2009; 611():389-91. PubMed ID: 19400237
[No Abstract] [Full Text] [Related]
5. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
6. Design of peptide-based inhibitors for human immunodeficiency virus type 1 strains resistant to T-20.
Izumi K; Kodama E; Shimura K; Sakagami Y; Watanabe K; Ito S; Watabe T; Terakawa Y; Nishikawa H; Sarafianos SG; Kitaura K; Oishi S; Fujii N; Matsuoka M
J Biol Chem; 2009 Feb; 284(8):4914-20. PubMed ID: 19073606
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of resistance to S138A substituted enfuvirtide and its application to peptide design.
Izumi K; Kawaji K; Miyamoto F; Shimane K; Shimura K; Sakagami Y; Hattori T; Watanabe K; Oishi S; Fujii N; Matsuoka M; Kaku M; Sarafianos SG; Kodama EN
Int J Biochem Cell Biol; 2013 Apr; 45(4):908-15. PubMed ID: 23357451
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of HIV-1 Resistance to an Electronically Constrained α-Helical Peptide Membrane Fusion Inhibitor.
Wu X; Liu Z; Ding X; Yu D; Wei H; Qin B; Zhu Y; Chong H; Cui S; He Y
J Virol; 2018 Apr; 92(7):. PubMed ID: 29321334
[TBL] [Abstract][Full Text] [Related]
9. Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors.
Eggink D; Langedijk JP; Bonvin AM; Deng Y; Lu M; Berkhout B; Sanders RW
J Biol Chem; 2009 Sep; 284(39):26941-50. PubMed ID: 19617355
[TBL] [Abstract][Full Text] [Related]
10. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
[TBL] [Abstract][Full Text] [Related]
11. Resistance to enfuvirtide, the first HIV fusion inhibitor.
Greenberg ML; Cammack N
J Antimicrob Chemother; 2004 Aug; 54(2):333-40. PubMed ID: 15231762
[TBL] [Abstract][Full Text] [Related]
12. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
[TBL] [Abstract][Full Text] [Related]
13. Heptad-repeat-2 mutations enhance the stability of the enfuvirtide-resistant HIV-1 gp41 hairpin structure.
Jenwitheesuk E; Samudrala R
Antivir Ther; 2005; 10(8):893-900. PubMed ID: 16430194
[TBL] [Abstract][Full Text] [Related]
14. Design of a novel HIV-1 fusion inhibitor that displays a minimal interface for binding affinity.
Oishi S; Ito S; Nishikawa H; Watanabe K; Tanaka M; Ohno H; Izumi K; Sakagami Y; Kodama E; Matsuoka M; Fujii N
J Med Chem; 2008 Feb; 51(3):388-91. PubMed ID: 18197613
[TBL] [Abstract][Full Text] [Related]
15. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
[TBL] [Abstract][Full Text] [Related]
16. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
[TBL] [Abstract][Full Text] [Related]
17. Full fusion competence rescue of the enfuvirtide resistant HIV-1 gp41 genotype (43D) by a prevalent polymorphism (137K).
Tolstrup M; Selzer-Plön J; Laursen AL; Bertelsen L; Gerstoft J; Duch M; Pedersen FS; Ostergaard L
AIDS; 2007 Feb; 21(4):519-21. PubMed ID: 17301572
[No Abstract] [Full Text] [Related]
18. Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Pan C; Cai L; Lu H; Qi Z; Jiang S
J Virol; 2009 Aug; 83(16):7862-72. PubMed ID: 19493996
[TBL] [Abstract][Full Text] [Related]
19. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
[TBL] [Abstract][Full Text] [Related]
20. Selection of T1249-resistant human immunodeficiency virus type 1 variants.
Eggink D; Baldwin CE; Deng Y; Langedijk JP; Lu M; Sanders RW; Berkhout B
J Virol; 2008 Jul; 82(13):6678-88. PubMed ID: 18434391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]